Synthetic Hybrids of Elymus canadensis x Sitanion hystrix

1967 ◽  
Vol 128 (1) ◽  
pp. 11-16 ◽  
Author(s):  
Douglas R. Dewey



1968 ◽  
Vol 129 (4) ◽  
pp. 309-315 ◽  
Author(s):  
Douglas R. Dewey


1986 ◽  
Vol 28 (6) ◽  
pp. 947-953 ◽  
Author(s):  
Richard R. -C. Wang ◽  
C. Hsiao

Hybrids of Elymus canadensis (2n = 28; SSHH) × Critesion californicum (2n = 14) and E. canadensis × C. bulbosum (2n = 14) were synthesized at relative frequencies of 11.8 and 0.3%, respectively, by the aid of embryo rescue techniques. A natural hybrid was identified as C. violaceum × C. bogdanii (2n = 14) by a combination of karytotype analysis and plant morphology. Gross spike morphology of the hybrids was intermediate to that of the parents. Meiotic chromosome pairings in these hybrids suggested that the genome of C. californicum and C. bogdanii is more or less homologous with one of the two genomes of E. canadensis. Genomes of C. violaceum and C. bulbosum appeared to be different from each other and from those in C. bogdanii and C. californicum. Based on the data in this study and others, the degree of genome differentiation among some Critesion and some Elymus species containing the H genome was examined and discussed. The symbol H is proposed for the genome in C. bogdanii and C. californicum, Hv for C. violaceum, Hb for C. bulbosum, and Hc for C. chilense.Key words: interspecific hybrids, synapsis, phylogeny, Hordeum, Elymus, Critesion.





1968 ◽  
Vol 129 (4) ◽  
pp. 316-322 ◽  
Author(s):  
Douglas R. Dewey


1965 ◽  
Vol 92 (6) ◽  
pp. 468 ◽  
Author(s):  
Douglas R. Dewey




1959 ◽  
Vol 37 (6) ◽  
pp. 1143-1151 ◽  
Author(s):  
Wray M. Bowden

Chromosome numbers and voucher specimens are recorded for some collections of the tribe TRITICEAE Dumort., mainly collected in Canada. The somatic chromosome numbers of the following are recorded: (1) Elymus canadensis L., 2n = 28; (2) Elymus cinereus Scribn. & Merr., 2n = 28 and 2n = 56; (3) Elymus glaucus Buckl., 2n = 28; (4a) Elymus innovatus Beal subsp. innovatus, 2n = 28; (4b) Elymus innovatus Beal subsp. velutinus Bowden, 2n = 56; (5) Elymus wiegandii Fern., 2n = 28; (6) Eremopyrum triticeum (Gaertn.) Nevski, 2n = 14; (7) Sitanion hystrix (Nutt.) J. G. Smith, 2n = 28; (8) × Agrohordeum macounii (Vasey) Lepage, 2n = 28; (9) × Agroelymushirtiflorus (Hitchc.) Bowden, 2n = 28; and (10) × Agroelymus ungavensis (Louis-Marie) Lepage, 2n = 28. Because var. coreensis Hack. is an earlier varietal name, Elymus mollis Trin. var. coreensis (Hack.) Bowden replaces E. mollis Trin. var. japonicus Bowden as the name for the variety that occurs on the shores of the Sea of Japan.



2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Victor Moreira de Oliveira ◽  
Matheus Nunes da Rocha ◽  
Emanuel Paula Magalhães ◽  
Francisco Rogênio da Silva Mendes ◽  
Márcia Machado Marinho ◽  
...  

Abstract Background The sanitary emergency installed in the world, generated by the pandemic of COVID-19, instigates the search for scientific strategies to mitigate the damage caused by the disease to different sectors of society. The disease caused by the coronavirus, SARS-CoV-2, reached 216 countries/territories, where about 199 million people were reported with the infection. Of these, more than 4 million died. In this sense, strategies involving the development of new antiviral molecules are extremely important. The main protease (Mpro) from SARS-CoV-2 is an important target, which has been widely studied for antiviral treatment. This work aims to perform a screening of pharmacodynamics and pharmacokinetics of synthetic hybrids from thymoquinone and artemisin (THY-ART) against COVID-19. Results Molecular docking studies indicated that hybrids of artemisinin and thymoquinone showed a relevant interaction with the active fraction of the enzyme Mpro, when compared to the reference drugs. Furthermore, hybrids show an improvement in the interaction of substances with the enzyme, mainly due to the higher frequency of interactions with the Thr199 residue. ADMET studies indicated that hybrids tend to permeate biological membranes, allowing good human intestinal absorption, with low partition to the central nervous system, potentiation for CYP-450 enzyme inhibitors, low risk of toxicity compared to commercially available drugs, considering mainly mutagenicity and cardiotoxicity, low capacity of hybrids to permeate the blood–brain barrier, high absorption and moderate permeability in Caco-2 cells. In addition, T1–T7 tend to have a better distribution of their available fractions to carry out diffusion and transport across cell membranes, as well as increase the energy of interaction with the SARS-CoV-2 target. Conclusions Hybrid products of artemisinin and thymoquinone have the potential to inhibit Mpro, with desirable pharmacokinetic and toxicity characteristics compared to commercially available drugs, being indicated for preclinical and subsequent clinical studies against SARS-CoV-2. Emphasizing the possibility of synergistic use with currently used drugs in order to increase half-life and generate a possible synergistic effect. This work represents an important step for the development of specific drugs against COVID-19.



Sign in / Sign up

Export Citation Format

Share Document